Division of Mylan NV
Latest From Viatris GmbH
Pfizer's biosimilars franchise is well on its way to becoming a blockbuster business, three years after the company launched its first US biosimilar.
Pfizer's biosimilar franchise is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
- Medical Devices
- Drug Delivery
- Therapeutic Areas
- Asta Medica AG
- Western Europe
- Parent & Subsidiaries
- Mylan NV
- Senior Management
Markus Peterseim, CEO
Paul Taaffe, CFO
Harald Borbe, CSO
Dirk Groen, SVP, Strategic Mktg. & Bus. Dev.
- Contact Info
Phone: (49) 69 4001 2812
P.O. Box 100105 Frankfurt am Main, D-60314
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.